FROM YAHOO NEWS Latest news, live updates as 2024 election results loom Canadian Sec - Delayed Quote ? CAD BioVaxys Technology Corp. (BIOV.CN) Follow Compare 0.0700 0.0000 (0.00%) At close: November 5 at 3:56 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine Development Consortium BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has been invited to and joined The Rapid Response Partnership Vehicle (RRPV), a consortium of large and small biopharma, contractors, government agencies, and academic and non-profit research institutions that support the US Government's Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure product and technolo CNW Group ? 14 hours ago BVAXF +0.37% BioVaxys' DPX Exhibits Superior Immune System Activation Compared to Aqueous and Emulsion-Based Antigen Delivery Systems BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights studies showing that its novel immune educating delivery platform, DPX?, recruits and activates unique subsets of antigen presenting cells ("APCs") to drive immunogenicity of antigens, and exhibits superior immune activation compared to aqueous and emulsion-based antigen delivery systems. CNW Group ? 5 days ago BVAXF +0.37% Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now MIAMI, Oct. 29, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 76th Emerging Growth Conference on October 30 & 31, 2024. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp GlobeNewswire ? 7 days ago VOXR BVAXF +0.37% CIA BioVaxys to Present at the Emerging Growth Conference on October 30th, 2024 BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX? platform to treat a range of cancers, infectious diseases, and immune modulated disorders is pleased to announce that Chief Executive Officer James Passin has been invited to present live at the Emerging Growth Conference on October 30th, 2024 at 9:40 AM EST. This live interactive online event will give CNW Group ? 8 days ago BVAXF +0.37% OTC Markets Hosts Virtual Investor Presentation with James Passin, Founder & CEO of BioVaxys Technology Corp, and Brad Sorensen, Senior Analyst at Zacks SCR OTCQB:BVAXF | CSE:BIOV OTC Markets: Hello and welcome to Virtual Investor Conferences. My name is Cecilia, and on behalf of OTC Markets, as well as our co-host Zacks Small Cap Research, we're very pleased you've joined us for our next live presentation from BioVaxys Technology. Their session will be moderated by Brad Sorensen, Senior Equity Research Analyst with Zacks Small Cap Research. Please Zacks Small Cap Research ? 22 days ago BVAXF +0.37% BioVaxys Engages Dr. Rajkannan Rajagopalan as Vaccine Formulations Advisor BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has engaged Rajkannan Rajagopalan, PhD, as Advisor for development and production of the Company's DPX? formulations. CNW Group ? 28 days ago BVAXF +0.37% BIOVAXYS ANNOUNCES CLOSING OF FIFTH TRANCHE OF PRIVATE PLACEMENT BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the fifth tranche (the "Fifth Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 4,500,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $225,000.00. Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole Share purchas CNW Group ? last month BVAXF +0.37% BIOVAXYS ANNOUNCES CLOSING OF FOURTH TRANCHE OF PRIVATE PLACEMENT BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 3,000,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $150,000.00. Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole Share purch CNW Group ? last month BVAXF +0.37% BIOVAXYS ANNOUNCES UPSIZING OF PRIVATE PLACEMENT BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce an increase to its previously announced non-brokered private placement offering of units of the Company ("Units") at a price of $0.05 per Unit (the "Private Placement"). Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant"), whereby each Warrant is exercisable for one additional Common Share at an exercise price of $0.15 for a period CNW Group ? last month BVAXF +0.37% Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Virtual Investor Forum held September 19th are now available for online viewing. This event was co-sponsored by Zacks Small-Cap Research. REGISTER NOW AT: https://bit.ly/3TuSFdy The company presentations will be available 24/ GlobeNewswire ? last month BVAXF +0.37% EVAX PLX BioVaxys Technology Corp. to Present at the Life Sciences Investor Forum September 19th 2024 BioVaxys invites individual and institutional investors, as well as advisors and analysts, to attend online at www.VirtualInvestorConferences.comVANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX? platform to treat a range of cancers, infectious diseases, and immune modulated disorders is pl GlobeNewswire ? last month BVAXF +0.37% Life Sciences Virtual Investor Forum Agenda Announced for September 19th Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Virtual Investor Forum to be held September 19th. This event is co-sponsored by Zacks Small-Cap Research Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER NOW AT: https://bit.ly/3XnsBlt It GlobeNewswire ? last month BVAXF +0.37% AEMD PLX BioVaxys to Present at the Life Sciences Investor Forum on September 19th BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX? platform to treat a range of cancers, infectious diseases, and immune modulated disorders is pleased to announce that Chief Executive Officer James Passin has been invited to present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19th, 2024. PR Newswire ? last month BVAXF +0.37% BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has closed the third tranche (the "Third Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 6,100,000 units (the "Units") of the Company at a price of $0.05 per Unit for aggregate gross proceeds of $305,000.00. CNW Group ? last month BVAXF +0.37% BioVaxys to Present New Data on its DPX Immune Educating Platform at Personalized Cancer Vaccine Summit BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") is pleased to announce that it has been invited to present "A Novel Delivery System for Personalized Peptide & mRNA Vaccines for More Targeted Therapies" at The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) to be held December 3-5, 2024, in Boston, MA. CNW Group ? 2 months ago BVAXF +0.37% BioVaxys DPX-Based Vaccines Exhibit Robust Efficacy Across Multiple Infectious Diseases BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") highlights the potential of its novel lipid-in-oil delivery platform, DPX?, across multiple infectious disease studies and announces its plans for partnering and further development. PR Newswire ? 2 months ago BVAXF +0.37% SPAYVAC FOR WILDLIFE, INC. ANNOUNCES COMPLETION OF SPAYVAC RESEARCH AND PRODUCTION FACILITY IN MADISON, WISCONSIN BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac for Wildlife, Inc. ("SpayVac") jointly announce that SpayVac? recently completed set-up of its new research and production facility in Madison, Wisconsin to produce their long-lasting, single-dose veterinary contraceptive vaccines. PR Newswire ? 2 months ago BVAXF +0.37% Biovaxys Signs Binding Letter of Intent to Develop DPX?-Based Vaccines for Life Threatening Food Allergies BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX? platform, is pleased to announce that it has executed a binding Letter of Intent ("Agreement") with AP Visionaries, Inc. of Ontario ("APVI") to jointly develop a proprietary DPX? formulation to address the urgent need for a therapy to treat or alleviate the potentially life-threatenin CNW Group ? 3 months ago BVAXF +0.37% BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT AND DEBT SETTLEMENT BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") consisting of up to 10,000,000 units ("Units") at a price of $0.05 per Unit for total gross proceeds of CAD $500,000, before deducting any offering-related expenses. Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant"). Each Warrant is exercisabl CNW Group ? 3 months ago BVAXF +0.37% BIOVAXYS ANNOUNCES ISSUANCE OF DPX RELATED PATENT FROM THE U.S. PATENT AND TRADEMARK OFFICE BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that the United States Patent and Trademark Office ("USPTO") has issued BioVaxys U.S. Patent No. 12,042,537. ("Patent") for inducing an antibody immune response from a low dose volume delivery of a B-cell epitope formulated with DPX?. PR Newswire ? 3 months ago BVAXF +0.37% Performance Overview Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return BIOV.CN S&P/TSX Composite index YTD +40.00% +16.36% 1-Year +180.00% +23.02% 3-Year -81.08% +14.27%
